On September 7, 2005, the Federal Circuit in In re Fisher upheld the PTO’s final rejection for lack of utility of a patent application for certain DNA sequence fragments generated from maize plants. The court, supporting a heightened utility standard, adopted the “real-world” test for establishing substantial and specific utility required by the PTO. This decision severely limits the granting of patent rights to DNA sequence fragments, which are capable of having value within the biotech community as research tools. This comment proposes the restoration of a less stringent utility standard to more correctly reflect the purposes of patent law and advocates the use of licensing regulations as a solution to the DNA-patenting dilemma
This Article introduces the scientific background necessary to understand the practice of gene seque...
Since the mapping of the human genome and the technical innovations in the field of biotechnology, p...
This editorial examines the logical structure of the United States Supreme Court decision in Myriad ...
On September 7, 2005, the Federal Circuit in In re Fisher upheld the PTO’s final rejection for lack ...
This Comment examines the newly revised PTO utility examination guidelines for biotechnology patents...
In In re Deuel, the United States Court of Appeals for the Federal Circuit ruled in favor of a paten...
At issue is whether or not isolated DNA is patent eligible under the U.S. Patent Law and the implica...
Concerns about the alleged harmful effects of gene patents— including hindered research and innovati...
The United States Patent and Trademark Office (PTO) recently finalized its patent utility guidelines...
In June 2013, in Ass’n for Molecular Pathology et. al., v. Myriad Genetics, Inc., the Supreme Court ...
As public and private sector initiatives raced to complete the sequence of the human genome, patent ...
The district court\u27s decision in Ass\u27n for Molecular Pathology v. U.S. Patent & Trademark Offi...
The High Court in D’Arcy v Myriad Genetics Inc. recently addressed patent claims under the Patents A...
In November 2000, the Genetic Services Committee of the National Society of Genetic Counselors (NSGC...
The emergence of genetic medicine following decades of molecular biology research has been accompa...
This Article introduces the scientific background necessary to understand the practice of gene seque...
Since the mapping of the human genome and the technical innovations in the field of biotechnology, p...
This editorial examines the logical structure of the United States Supreme Court decision in Myriad ...
On September 7, 2005, the Federal Circuit in In re Fisher upheld the PTO’s final rejection for lack ...
This Comment examines the newly revised PTO utility examination guidelines for biotechnology patents...
In In re Deuel, the United States Court of Appeals for the Federal Circuit ruled in favor of a paten...
At issue is whether or not isolated DNA is patent eligible under the U.S. Patent Law and the implica...
Concerns about the alleged harmful effects of gene patents— including hindered research and innovati...
The United States Patent and Trademark Office (PTO) recently finalized its patent utility guidelines...
In June 2013, in Ass’n for Molecular Pathology et. al., v. Myriad Genetics, Inc., the Supreme Court ...
As public and private sector initiatives raced to complete the sequence of the human genome, patent ...
The district court\u27s decision in Ass\u27n for Molecular Pathology v. U.S. Patent & Trademark Offi...
The High Court in D’Arcy v Myriad Genetics Inc. recently addressed patent claims under the Patents A...
In November 2000, the Genetic Services Committee of the National Society of Genetic Counselors (NSGC...
The emergence of genetic medicine following decades of molecular biology research has been accompa...
This Article introduces the scientific background necessary to understand the practice of gene seque...
Since the mapping of the human genome and the technical innovations in the field of biotechnology, p...
This editorial examines the logical structure of the United States Supreme Court decision in Myriad ...